Breaking Barriers.
Protecting Brains.
Investing in the Future of Neuroprotection
Breaking barriers in brain health with next-generation neuroprotective therapies. Targeting the root causes of neurodegeneration in Alzheimer’s and Multiple Sclerosis.
Our Mission
At Bivium Biosciences, our mission is to revolutionize the treatment of neurodegenerative diseases like Multiple Sclerosis and Alzheimer’s Disease. We are doing this by delivering innovative, brain-penetrant therapeutics that provide precise and effective neuroprotection.
Problem
Current treatments for neurodegenerative disorders often focus on secondary processes like inflammation (for MS) and aberrant plaque accumulation (for AD). While these approaches have shown some clinical promise, remissions are often short-lived and relapses are very common.
Solution
Several recent discoveries made by our team have identified key molecular players involved in the glutamate-mediated neurodegenerative cascade, uncovering novel therapeutic entry points to address the root causes of these devastating diseases.
About Bivium Biosciences
At Bivium Biosciences, our mission is to revolutionize the treatment of neurodegenerative diseases like Multiple Sclerosis and Alzheimer’s Disease.
Phil on Bivium’s Mission: Advancing Neuroprotection for Alzheimer’s & MS with Cleveland Clinic
Our Science: The Foundation
Our approach combats neurodegeneration in MS and AD in a novel way. To fully appreciate the innovation of this strategy, it is essential to understand the root causes of these diseases, and the shortcomings of current therapeutic options.
The Foundation w/ Dr. Tara DeSilva
Sit back, relax, and let Bivium’s scientific inventor, Dr. Tara DeSilva, walk you through our scientific approach – starting with the pathology and current treatments for MS and AD.
Why Invest in Bivium?
Virtual Laboratory Tour
Take a guided tour through our state-of-the-art research facilities.
Leadership Team
Meet the team, scientific leaders, and investors supporting BIVIUM Biosciences
Philippe Deschamps
President & CEO
Philippe Deschamps brings extensive experience in the global healthcare industry, where he has led four companies as CEO.
Tara DeSilva, PhD
Scientific Inventor
Dr. Tara DeSilva is an Associate Professor at the Cleveland Clinic with 15+ years of investigating neuroinflammation and mechanisms of cell death.
Brian Cogley
CFO
We have engaged Little Creek Capital Advisors, LLC. to provide CFO services. Brian Cogley serves as the acting CFO.